CNMD Quote, Financials, Valuation and Earnings

Inspire Medical Systems, Inc. has a net margin of 0.84% compared to CONMED Corp.'s net margin of 4.42%. CONMED Corp.'s return on equity of 6.56% beat Inspire Medical Systems, Inc.'s return on equity of 6.62%.

CONMED Corp. has a consensus price target of $56.00, signalling upside risk potential of 22.06%. On the other hand Inspire Medical Systems, Inc. has an analysts' consensus of $123.07 which suggests that it could fall by -12.11%. Given that CONMED Corp. has higher upside potential than Inspire Medical Systems, Inc., analysts believe CONMED Corp. is more attractive than Inspire Medical Systems, Inc..

CONMED Corp. has a beta of 0.977, which suggesting that the stock is 2.326% less volatile than S&P 500. In comparison Inspire Medical Systems, Inc. has a beta of 0.696, suggesting its less volatile than the S&P 500 by 30.412%.

CONMED Corp. has a quarterly dividend of $0.20 per share corresponding to a yield of 1.81%. Inspire Medical Systems, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CONMED Corp. pays 18.82% of its earnings as a dividend. Inspire Medical Systems, Inc. pays out -- of its earnings as a dividend. CONMED Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

CONMED Corp. quarterly revenues are $338.6M, which are larger than Inspire Medical Systems, Inc. quarterly revenues of $224.5M. CONMED Corp.'s net income of $2.9M is lower than Inspire Medical Systems, Inc.'s net income of $9.9M. Notably, CONMED Corp.'s price-to-earnings ratio is 21.48x while Inspire Medical Systems, Inc.'s PE ratio is 96.05x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CONMED Corp. is 1.02x versus 4.77x for Inspire Medical Systems, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Myomo, Inc. has a net margin of 0.84% compared to CONMED Corp.'s net margin of -36.3%. CONMED Corp.'s return on equity of 6.56% beat Myomo, Inc.'s return on equity of -68.35%.

CONMED Corp. has a consensus price target of $56.00, signalling upside risk potential of 22.06%. On the other hand Myomo, Inc. has an analysts' consensus of $5.00 which suggests that it could grow by 390.2%. Given that Myomo, Inc. has higher upside potential than CONMED Corp., analysts believe Myomo, Inc. is more attractive than CONMED Corp..

CONMED Corp. has a beta of 0.977, which suggesting that the stock is 2.326% less volatile than S&P 500. In comparison Myomo, Inc. has a beta of 1.026, suggesting its more volatile than the S&P 500 by 2.583%.

CONMED Corp. has a quarterly dividend of $0.20 per share corresponding to a yield of 1.81%. Myomo, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CONMED Corp. pays 18.82% of its earnings as a dividend. Myomo, Inc. pays out -- of its earnings as a dividend. CONMED Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

CONMED Corp. quarterly revenues are $338.6M, which are larger than Myomo, Inc. quarterly revenues of $10.1M. CONMED Corp.'s net income of $2.9M is higher than Myomo, Inc.'s net income of -$3.7M. Notably, CONMED Corp.'s price-to-earnings ratio is 21.48x while Myomo, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CONMED Corp. is 1.02x versus 1.00x for Myomo, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Phibro Animal Health Corp. has a net margin of 0.84% compared to CONMED Corp.'s net margin of 7.29%. CONMED Corp.'s return on equity of 6.56% beat Phibro Animal Health Corp.'s return on equity of 24.77%.

CONMED Corp. has a consensus price target of $56.00, signalling upside risk potential of 22.06%. On the other hand Phibro Animal Health Corp. has an analysts' consensus of $43.00 which suggests that it could grow by 5.47%. Given that CONMED Corp. has higher upside potential than Phibro Animal Health Corp., analysts believe CONMED Corp. is more attractive than Phibro Animal Health Corp..

CONMED Corp. has a beta of 0.977, which suggesting that the stock is 2.326% less volatile than S&P 500. In comparison Phibro Animal Health Corp. has a beta of 0.771, suggesting its less volatile than the S&P 500 by 22.868%.

CONMED Corp. has a quarterly dividend of $0.20 per share corresponding to a yield of 1.81%. Phibro Animal Health Corp. offers a yield of 1.18% to investors and pays a quarterly dividend of $0.12 per share. CONMED Corp. pays 18.82% of its earnings as a dividend. Phibro Animal Health Corp. pays out 40.46% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

CONMED Corp. quarterly revenues are $338.6M, which are smaller than Phibro Animal Health Corp. quarterly revenues of $363.9M. CONMED Corp.'s net income of $2.9M is lower than Phibro Animal Health Corp.'s net income of $26.5M. Notably, CONMED Corp.'s price-to-earnings ratio is 21.48x while Phibro Animal Health Corp.'s PE ratio is 24.51x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CONMED Corp. is 1.02x versus 1.19x for Phibro Animal Health Corp.. Usually stocks with elevated PS ratios are considered overvalued.

Stereotaxis, Inc. has a net margin of 0.84% compared to CONMED Corp.'s net margin of -86.59%. CONMED Corp.'s return on equity of 6.56% beat Stereotaxis, Inc.'s return on equity of -218.3%.

CONMED Corp. has a consensus price target of $56.00, signalling upside risk potential of 22.06%. On the other hand Stereotaxis, Inc. has an analysts' consensus of $4.25 which suggests that it could grow by 74.9%. Given that Stereotaxis, Inc. has higher upside potential than CONMED Corp., analysts believe Stereotaxis, Inc. is more attractive than CONMED Corp..

CONMED Corp. has a beta of 0.977, which suggesting that the stock is 2.326% less volatile than S&P 500. In comparison Stereotaxis, Inc. has a beta of 1.472, suggesting its more volatile than the S&P 500 by 47.244%.

CONMED Corp. has a quarterly dividend of $0.20 per share corresponding to a yield of 1.81%. Stereotaxis, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. CONMED Corp. pays 18.82% of its earnings as a dividend. Stereotaxis, Inc. pays out -- of its earnings as a dividend. CONMED Corp.'s payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

CONMED Corp. quarterly revenues are $338.6M, which are larger than Stereotaxis, Inc. quarterly revenues of $7.5M. CONMED Corp.'s net income of $2.9M is higher than Stereotaxis, Inc.'s net income of -$6.5M. Notably, CONMED Corp.'s price-to-earnings ratio is 21.48x while Stereotaxis, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for CONMED Corp. is 1.02x versus 7.16x for Stereotaxis, Inc.. Usually stocks with elevated PS ratios are considered overvalued.